Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 11/20 | 0.55 |
| ▸ | KIT | P10721 | 4/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20074099 | 0.89 | KDM5B (0.50) | KDM5BKITKDM5AKDM5CKDM4C | |
| SCHEMBL20074306 | 0.89 | KDM5B (0.55) | KDM5BKITKDM5AKDM5CKDM4C | |
| SCHEMBL20074143 | 0.86 | KDM5B (0.41) | KDM5BKDM5AKDM5CKDM4CTSHR | |
| SCHEMBL21681722 | 0.81 | KDM5B (0.54) | KDM5BKITKDM5AKDM5CTSHR | |
| SCHEMBL21720927 | 0.81 | KDM5B (0.51) | KDM5BKDM5ATSHR | |
| SCHEMBL21721735 | 0.81 | KDM5B (0.47) | KDM5BKDM5ATSHR | |
| SCHEMBL20074329 | 0.80 | KDM5B (0.52) | KDM5BKDM5ATSHR | |
| SCHEMBL21681711 | 0.80 | KDM5B (0.48) | KDM5BKDM5ATSHR | |
| SCHEMBL21721867 | 0.79 | KDM5B (0.53) | KDM5BKDM5ATSHR | |
| SCHEMBL20074100 | 0.78 | KDM5B (0.53) | KDM5BKDM5ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525785-B1 | KDM5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-08-27 | — | — | EP | claimed |
| EP-3525785-B1 | KDM5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-10975084-B2 | KDM5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200048258-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048258-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | KDM5B 2/4885KIT 911/4885KDM5A 1/4885 |
| US-10975084-B2 | KDM5 inhibitors | KDM5A, KDM5B, KDM5C | KDM5B 2/4885KIT 911/4885KDM5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.